Journal article

Effects of Gefitinib, an Epidermal Growth Factor Receptor Inhibitor, on Human Placental Cell Growth

Ulrika W Nilsson, Terrance G Johns, Tania Wilmann, Tu'uhevaha Kaitu'u-Lino, Clare Whitehead, Eva Dimitriadis, Ellen Menkhorst, Burcu Saglam, Yane Gao, Sameer A Greenall, Andrew W Horne, Stephen Tong

OBSTETRICS AND GYNECOLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2013

Abstract

OBJECTIVE: Placenta has the highest expression of epidermal growth factor (EGF) receptor of all tissues, a cell signaling pathway promoting survival and growth. Therefore, EGF receptor inhibition could potentially treat ectopic pregnancy. We undertook preclinical studies to examine whether gefitinib (orally available EGF receptor inhibitor) with or without methotrexate inhibits placental cell growth. METHODS: Gefitinib and methotrexate were added to placental cells and their ability inhibit cell growth, block EGF receptor signaling, and induce apoptosis (programmed cell death) was examined. They were also administered to two animal mouse models to examine their effects on placental tissue in..

View full abstract

Grants

Awarded by National Health and Medical Research Council of Australia (NHMRC) Project


Awarded by NHMRC Career Development Fellowship


Awarded by NHMRC Training Fellowships


Awarded by MRC Centenary Award


Awarded by Medical Research Council


Funding Acknowledgements

Supported by the National Health and Medical Research Council of Australia (NHMRC) Project Grants 606611 (S. T. and T.G.J.), 1008276 (S. T., and T.G.J.), and 550905 (to E. D.); NHMRC Career Development Fellowship #1050765 (S. T.) and NHMRC Training Fellowships #550911 (E. D.); Medical Research Council (MRC) Clinician Scientist Fellowship and MRC Centenary Award #G0802808 (A. W. H.); The Helen MacPherson Trust (S. T.); The Arthur Wilson RANZCOG Fellowship (S. T.) and The Monash University Strategic Grants Scheme (S. T.); and The Victorian Government's Operational Infrastructure Support Program (T.G.J., S. T., and U.W.N.).